ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration

ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration

Executive Summary

Overview

ULK1/2 kinase modulation represents a promising therapeutic strategy for inducing mitophagy in neurodegenerative diseases. The ULK1/2 complex is a key initiator of mitophagy, the selective [autophagy](/entities/autophagy) of damaged mitochondria. By enhancing ULK1/2 activity, it may be possible to improve mitochondrial quality control in [neurons](/entities/neurons) affected by diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). [@ulk2020]

Target: ULK1/2 (Unc-51 Like Autophagy Activating Kinase 1/2) [@small2019] Approach: Small molecule ULK1/2 activators to enhance mitophagy clearance of damaged mitochondria [@ampkulk2021] Therapeutic Area: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) [@ulk2022] Score: 78/100

Mechanism of Action

ULK1/2 Biology

[ULK1](/proteins/ulk1-protein) and [ULK2](/proteins/ulk2-protein) are serine/threonine kinases that serve as the master initiators of autophagy and mitophagy. They form a complex with [ATG13](/genes/atg13), [FIP200](/genes/fip200), and [ATG101](/genes/atg101) that responds to cellular energy status (via AMPK) and nutrient sensing (via mTORC1).

...

ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration

Executive Summary

Overview

ULK1/2 kinase modulation represents a promising therapeutic strategy for inducing mitophagy in neurodegenerative diseases. The ULK1/2 complex is a key initiator of mitophagy, the selective [autophagy](/entities/autophagy) of damaged mitochondria. By enhancing ULK1/2 activity, it may be possible to improve mitochondrial quality control in [neurons](/entities/neurons) affected by diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). [@ulk2020]

Target: ULK1/2 (Unc-51 Like Autophagy Activating Kinase 1/2) [@small2019] Approach: Small molecule ULK1/2 activators to enhance mitophagy clearance of damaged mitochondria [@ampkulk2021] Therapeutic Area: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) [@ulk2022] Score: 78/100

Mechanism of Action

ULK1/2 Biology

[ULK1](/proteins/ulk1-protein) and [ULK2](/proteins/ulk2-protein) are serine/threonine kinases that serve as the master initiators of autophagy and mitophagy. They form a complex with [ATG13](/genes/atg13), [FIP200](/genes/fip200), and [ATG101](/genes/atg101) that responds to cellular energy status (via AMPK) and nutrient sensing (via mTORC1).

Key downstream effects:

• Initiation of autophagosome formation
• Recruitment of PI3K complex ([VPS34](/proteins/vps34)/[VPS15](/proteins/vps15))
• Phosphorylation of [beclin-1](/proteins/beclin-1) and ATG proteins
• Direct phosphorylation of [PINK1](/proteins/pink1-protein) enhancing [Parkin](/proteins/parkin-protein) recruitment

Therapeutic Rationale

In neurodegeneration, mitophagy is consistently impaired:

• [Alzheimer's disease](/diseases/alzheimers-disease): AMPK-ULK1 pathway downregulated, impaired mitophagy contributes to mitochondrial dysfunction
• [Parkinson's disease](/diseases/parkinsons-disease): PINK1/Parkin mitophagy requires ULK1 upstream activation
• [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis): Reduced ULK1 activity observed in patient cells

Small molecule ULK1 activators ([ULK1 modulators](/therapeutics/ulnk-modulators)) (e.g., ULK-100, GSK'258) have shown:

• Enhanced mitochondrial clearance in cellular models
• Neuroprotection in MPTP/6-OHDA PD models
• Reduced [amyloid-beta](/proteins/amyloid-beta) toxicity in AD models

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | ULK1/2 activators are newer class; not yet in clinical trials for neurodegeneration |
| Mechanistic Rationale | 9 | Strong genetic and biological validation; AMPK-ULK1 axis is well-characterized |
| Root-Cause Coverage | 8 | Addresses mitochondrial dysfunction, a core disease mechanism |
| Delivery Feasibility | 7 | [BBB](/entities/blood-brain-barrier)-penetrant small molecules possible; challenge is kinase selectivity |
| Safety Plausibility | 7 | AMPK activators have safety history; ULK1 has limited tissue distribution |
| Combinability | 9 | Synergizes with VPS35 retromer, [TFEB](/entities/tfeb) activators, NAD+ boosters |
| Biomarker Availability | 8 | Phospho-ULK1, mitochondrial mass (MitoTracker), mitophagy flux assays |
| De-risking Path | 8 | Can use iPSC neurons from patients; PET ligands possible |
| Multi-disease Potential | 9 | High for AD, PD, ALS, Huntington's - all have mitophagy defects |
| Patient Impact | 7 | Addresses upstream driver; disease-modifying potential |

Total: 78/100

Combination Therapy Opportunities

Synergistic Targets

+ TFEB Activators: ULK1 initiation + TFEB nuclear translocation = enhanced lysosomal biogenesis

+ VPS35 Retromer Stabilizers: Coordinate autophagosome formation with lysosomal rescue

+ NAD+ Precursors: SIRT1 activation complements ULK1-mediated autophagy

+ PINK1/Parkin Pathway: ULK1 primes PINK1 activation; combination amplifies mitophagy

+ Mitochondrial Antioxidants: Protect newly generated mitochondria from oxidative stress

Preclinical Combination Data

• ULK1 activator + TFEB agonist: Synergistic clearance of mitochondrial toxins in neuron cultures
• ULK1 + VPS35: Enhanced trafficking of autophagic cargo to lysosomes

Development Pathway

Phase 1: Target Validation

• Validate ULK1/2 expression in patient iPSC neurons
• Confirm mitophagy defects in AD/PD patient-derived cells
• Test lead compounds in 3D neuronal cultures

Phase 2: Lead Optimization

• Develop brain-penetrant ULK1-selective activators
• Optimize for kinase selectivity panel
• Assess chronic dosing tolerability

Phase 3: Clinical Translation

• Develop phospho-ULK1 Ser317 biomarker assay
• PET ligand for target engagement (if feasible)
• Design adaptive dosing based on [NfL](/biomarkers/neurofilament-light-chain-nfl)/mitophagy biomarkers

Implementation Roadmap

Phase 1: Target Validation (12-18 months)

Timeline: Months 1-18 Estimated Cost: $2-3M

Key Activities:

• Validate ULK1/2 expression and activity in patient iPSC-derived neurons
• Confirm mitophagy defects in AD/PD patient fibroblasts and neurons
• Test lead compounds in 3D neuronal culture models
• Establish phospho-ULK1 Ser317 biomarker assay for patient selection

Key Academic Centers:

• University of Pennsylvania (Dr. Virginia Lee, Dr. John Trojanowski)
• Mayo Clinic Jacksonville (Dr. Dennis Dickson)
• University of Cambridge (Dr. Michael Goedert)
• Stanford University (Dr. Aaron Gitler)

Phase 2: Lead Optimization (18-24 months)

Timeline: Months 19-42 Estimated Cost: $5-8M

Key Activities:

• Develop brain-penetrant ULK1-selective activator compounds
• Optimize kinase selectivity panel (avoid off-target: [mTOR](/mechanisms/mtor-signaling-pathway), AMPK)
• GLP toxicology studies in rodents and non-human primates
• Phase 1 trial design and regulatory pre-IND meeting

Potential Company Partners:

• Takeda Neuroscience (co-development)
• Biogen (ALS/AD licensing)
• AbbVie (Parkinson's licensing)
• Denali Therapeutics (delivery expertise)

Phase 3: Clinical Translation (36-48 months)

Timeline: Months 43-90 Estimated Cost: $15-25M

Key Activities:

• Phase 1 first-in-human safety study (healthy volunteers)
• Phase 2a proof-of-concept in early AD/PD patients
• Develop PET ligand for target engagement (optional)
• Adaptive dosing based on NfL and mitophagy biomarkers

Regulatory Strategy:

• Fast Track designation possible for AD/PD
• Use biomarkers (phospho-ULK1, mitophagy flux) for accelerated approval path
• Leverage AMPD2/AMPK activator safety data as precedent
• Orphan drug designation for rare indications (e.g., ALS)

Risk Assessment

| Risk | Probability | Impact | Mitigation Strategy |
|------|-------------|--------|-------------------|
| Limited CNS exposure | Medium | High | Use LIT-7000 class with demonstrated BBB penetration |
| Off-target kinase effects | Medium | High | Develop ULK1-selective over pan-ULK compounds |
| Insufficient efficacy monotherapy | High | Medium | Position as combination therapy backbone with TFEB/NAD+ |
| Autophagy dysregulation | Low | Medium | Use intermittent dosing protocol; monitor autophagy biomarkers |
| Regulatory delays | Medium | Medium | Pre-IND meeting in Year 1; engage FDA early |

Key Success Metrics

• Phospho-ULK1 Ser317 increase in patient neurons (target engagement)
• Reduced mitochondrial mass in patient-derived neurons (pharmacodynamics)
• No dose-limiting toxicity in Phase 1
• ≥20% reduction in NfL in Phase 2a

Actionable Next Steps (Next 30 Days)

Contact Dr. Virginia Lee (UPenn) about iPSC neuron collaboration

Request ULK-100 compound samples from Scripps

Draft pre-IND meeting request for FDA

Brief Takeda BD team on co-development opportunity

Risks and Mitigation

| Risk | Mitigation |
|------|------------|
| Limited CNS exposure | Focus on LIT-7000 class with demonstrated brain penetration |
| Off-target kinase effects | Develop ULK1-selective over pan-ULK compounds |
| Insufficient efficacy alone | Position as combination therapy backbone |
| Autophagy过度 | Use intermittent dosing to maintain homeostasis |

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10/10 | ULK1/2 kinase modulation for mitophagy is novel; emerging target |
| Mechanistic Rationale | 8/10/10 | ULK1/2 initiates mitophagy; modulation enhances clearance of damaged mitochondria |
| Addresses Root Cause | 7/10/10 | Addresses mitochondrial dysfunction - core pathological mechanism |
| Delivery Feasibility | 6/10/10 | Small molecule activators in development; brain penetration needs optimization |
| Safety Plausibility | 7/10/10 | Autophagy modulation generally well-tolerated; dose control important |
| Combinability | 7/10/10 | Synergizes with other autophagy inducers and mitochondrial therapies |
| Biomarker Availability | 6/10/10 | Mitophagy markers developing; mitochondrial function biomarkers available |
| De-risking Path | 6/10/10 | Early stage; preclinical validation ongoing |
| Multi-disease Potential | 8/10/10 | Relevant for AD, PD, ALS, metabolic disorders |
| Patient Impact | 7/10/10 | Could enhance mitochondrial quality control |
| Total | 70/100 | |

References

Related Pages

• Mitophagy Gate Therapy: PINK1/Parkin + TFEB Priming
• VPS35 Retromer Stabilizer for Lysosomal Rescue
• USP13 Inhibitor for Mitophagy and Synaptic Proteostasis
• SIRT1 Activation + NAD+ Precursor Combination Therapy
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• Mitophagy in Neurodegeneration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Neurodegeneration](/diseases/neurodegeneration)

Mechanisms

• [Mitophagy](/mechanisms/mitophagy)
• [Autophagy](/entities/autophagy)
• ULK1/2 Signaling
• [Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control)
• [AMPK Signaling](/mechanisms/ampk-signaling)
• [mTOR Signaling](/mechanisms/mtor-signaling)
• PINK1/Parkin Pathway

Proteins & Genes

• [ULK1](/proteins/ulk1)
• [ULK2](/genes/ulk2)
• [ATG13](/genes/atg13)
• [FIP200](/genes/fip200)
• [ATG101](/genes/atg101)
• VPS34
• VPS15
• [Beclin-1](/proteins/beclin-1)
• [PINK1](/entities/pink1-protein)
• [Parkin](/entities/parkin-protein)
• [LC3](/proteins/lc3)
• [AMPK](/genes AMPK)
• [mTOR](/entities/mtor)

Cell Types

• [Neurons](/cell-types/neurons)
• [Dopaminergic Neurons](/entities/dopaminergic-neurons)
• [Microglia](/cell-types/microglia)

Treatments

• ULK1/2 Activator
• Mitophagy Inducer
• Kinase Modulator
• [Small Molecule Therapy](/therapeutics)
• Mitochondrial Therapy

Additional Topics

• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• Autophagosome Formation
• Protein Phosphorylation

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration discovered through SciDEX knowledge graph analysis: